Lapatinib: a novel dual tyrosine kinase inhibitor
- Resource Type
- Authors
- Paul Ellis; Lisa M. Pickering; Simon Chowdhury
- Source
- Targeted Oncology. 2:107-112
- Subject
- Oncology
Cancer Research
medicine.medical_specialty
Future studies
biology
business.industry
medicine.drug_class
Subgroup analysis
medicine.disease
Lapatinib
Metastatic breast cancer
Tyrosine-kinase inhibitor
Breast cancer
Renal cell carcinoma
Internal medicine
biology.protein
Medicine
Pharmacology (medical)
Epidermal growth factor receptor
skin and connective tissue diseases
business
medicine.drug
- Language
- ISSN
- 1776-260X
1776-2596
Lapatinib is an active and well-tolerated oral dual tyrosine kinase inhibitor that is able to inhibit epidermal growth factor receptor (EGFR) and HER2 with high specificity. It has shown promising activity in several cancers most notably metastatic breast cancer. Lapatinib is active in both trastuzumab-refractory and -naive breast cancer and a number of phase III studies are ongoing to fully define its activity. Studies have also been conducted in a range of other cancers including renal cell carcinoma. It is essential that future studies incorporate predictive biomarker subgroup analysis. This will help to ensure that important subgroup activity is not missed and also allow the definition of groups most likely to benefit from lapatinib.